ID: ALA4129493

Max Phase: Preclinical

Molecular Formula: C30H21N3O5S

Molecular Weight: 535.58

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1ccc(-n2c(-c3cc4ccccc4oc3=O)cs/c2=N/NC(=O)c2cc3ccccc3oc2=O)c(C)c1

Standard InChI:  InChI=1S/C30H21N3O5S/c1-17-11-12-23(18(2)13-17)33-24(21-14-19-7-3-5-9-25(19)37-28(21)35)16-39-30(33)32-31-27(34)22-15-20-8-4-6-10-26(20)38-29(22)36/h3-16H,1-2H3,(H,31,34)/b32-30+

Standard InChI Key:  BMHRASKXCYGQNY-NHQGMKOOSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 535.58

Molecular Weight (Monoisotopic): 535.1202

AlogP: 5.28

#Rotatable Bonds: 4

Polar Surface Area: 106.81

Molecular Species: NEUTRAL

HBA: 8

HBD: 1

#RO5 Violations: 2

HBA (Lipinski): 8

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 9.89

CX Basic pKa: 0.05

CX LogP: 5.71

CX LogD: 5.71

Aromatic Rings: 6

Heavy Atoms: 39

QED Weighted: 0.24

Np Likeness Score: -1.07

References

1. Ibrar A, Shehzadi SA, Saeed F, Khan I..  (2018)  Developing hybrid molecule therapeutics for diverse enzyme inhibitory action: Active role of coumarin-based structural leads in drug discovery.,  26  (13): [PMID:30017112] [10.1016/j.bmc.2018.05.042]

2. Singh H, Singh JV, Bhagat K, Gulati HK, Sanduja M, Kumar N, Kinarivala N, Sharma S..  (2019)  Rational approaches, design strategies, structure activity relationship and mechanistic insights for therapeutic coumarin hybrids.,  27  (16): [PMID:31255497] [10.1016/j.bmc.2019.06.033]

Source

Source(1):

• Scientific Literature